Research into the differential roles of HIF-1α and HIF-2α in tumor biology continues to drive the development of more selective therapies, as targeting HIF-2α alone may provide specific benefits without the broader metabolic effects associated with pan-HIF inhibition [28]. The gene discussed is EPAS1; the disease is neoplasm.